Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Definitive Prostatic Radiation and Intermittent Androgen Deprivation Therapy
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; SD 101 Dynavax (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Oct 2017 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 13 Oct 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 13 Oct 2017 Status changed from recruiting to suspended.